Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies

• Үндсэн зохиолчид: Ferrufino CP (Зохиогч), Munakata J (Зохиогч), Wei W (Зохиогч), Proudfoot C (Зохиогч), Kuznik A (Зохиогч), Boklage SH (Зохиогч), Chen C (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Dove Medical Press, 2018-11-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Cheryl P Ferrufino,1 Julie Munakata,1 Wenhui Wei,2 Clare Proudfoot,3 Andreas Kuznik,4 Susan H Boklage,4 Chieh-I Chen4 1IQVIA, Fairfax, VA, USA; 2Sanofi, Bridgewater, NJ, USA; 3Sanofi, Guildford, UK; 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA Objective: To estimate the 5-year budge...